LAVIPHARM S.A. NA EO 1 (BXA0) — Working Capital to Net Assets Ratio
LAVIPHARM S.A. NA EO 1 (BXA0) has a Working Capital to Net Assets ratio of 11.1% as of December 2024. Working capital of €5.88 Million (current assets of €45.00 Million minus current liabilities of €39.12 Million) is measured against net assets of €52.97 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See BXA0 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
LAVIPHARM S.A. NA EO 1 Working Capital to Net Assets (2021–2024)
This chart shows how LAVIPHARM S.A. NA EO 1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 11.1%, reflecting working capital of €5.88 Million against net assets of €52.97 Million EUR. Check BXA0 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for LAVIPHARM S.A. NA EO 1 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see BXA0 market cap overview.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 11.1% | €5.88 Million | €52.97 Million | €45.00 Million | €39.12 Million | ▼ -11.9 pp |
| 2023 | 23.0% | €9.85 Million | €42.77 Million | €45.65 Million | €35.80 Million | ▲ +23.4 pp |
| 2022 | -0.3% | €-140.00K | €40.31 Million | €45.60 Million | €45.74 Million | ▼ -152.4 pp |
| 2021 | 152.0% | €-15.11 Million | €-9.94 Million | €25.96 Million | €41.07 Million | — |